search
Back to results

Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction (CRIDD)

Primary Purpose

Cardiac Surgery, Cardiopulmonary Bypass

Status
Active
Phase
Not Applicable
Locations
Italy
Study Type
Interventional
Intervention
Eurosets REMOWELL 2 oxygenator
LivaNova INSPIRE oxygenator
Sponsored by
Maria Cecilia Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Cardiac Surgery

Eligibility Criteria

65 Years - undefined (Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Signature of informed consent for participation in the study
  2. Age ≥65 years
  3. Patients undergoing cardiac surgery of:

    1. coronary artery bypass graft and concomitant valve replacement/repair OR
    2. double valve replacement/repair

Exclusion Criteria:

  1. Any documented history of cognitive impairment estimated as a mini mental state examination < 24 points
  2. Patients who need blood prime in the cardiopulmonary bypass circuit
  3. Chronic coagulopathies ( international normalized ratio > 2 in patients without anticoagulant treatment)
  4. End stage renal disease on dialysis treatment
  5. Previous cerebrovascular accident
  6. Active cancer or immunological diseases
  7. Liver cirrhosis (platelets <100.000/uL)
  8. Decompensated diabetes
  9. Severe preoperative anemia (hemoglobin <8 g/dl).

Sites / Locations

  • Maria Cecilia Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Eurosets REMOWELL 2 oxygenator

LivaNova INSPIRE oxygenator

Arm Description

Outcomes

Primary Outcome Measures

post-operative delirium
In-hospital incidence of post-operative delirium assessed by Confusion Assessment Method (CAM) diagnostic algorithm

Secondary Outcome Measures

Full Information

First Posted
August 19, 2019
Last Updated
July 11, 2023
Sponsor
Maria Cecilia Hospital
search

1. Study Identification

Unique Protocol Identification Number
NCT04062396
Brief Title
Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction
Acronym
CRIDD
Official Title
Randomized Comparison Between Oxygenator Systems for the Reduction of Post-operative Delirium in Older Patients Undergoing Cardiac Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
September 26, 2019 (Actual)
Primary Completion Date
June 26, 2022 (Actual)
Study Completion Date
September 2023 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Maria Cecilia Hospital

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Age is no longer an absolute contraindication to cardiac surgery therefore there is often need for combined interventions (double valve repair/replacement, or coronary artery bypass graft and valve repair/replacement) with relative prolongation of cardiopulmonary bypass time. Prolonged cardiopulmonary bypass use causes an increase in the inflammatory response, and on the other a need for blood reinfusion and therefore lipid microemboli from the operative field. The clinical consequences for patients are post-operative delirium and post-operative cognitive impairment. These two neurological complications involve up to 45% of elderly patients undergoing cardiac surgery and have a significant impact on quality of life, hospitalization and mortality in the short and long term. The Remowell 2 oxygenator system has demonstrated in preliminary studies that, compared to the gold standard Inspire oxygenator, it can guarantee a significant reduction of hemodilution, inflammatory systemic response and embolization of lipid microemboli and leukocytes. In light of these considerations, it is possible to formulate the hypothesis that the use of the Remowell 2 device can contribute to significantly reducing the onset of post-operative delirium and cognitive impairment. The present study is designed to validate this hypothesis in a randomized controlled scenario.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Cardiac Surgery, Cardiopulmonary Bypass

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
ParticipantOutcomes Assessor
Allocation
Randomized
Enrollment
314 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Eurosets REMOWELL 2 oxygenator
Arm Type
Active Comparator
Arm Title
LivaNova INSPIRE oxygenator
Arm Type
Active Comparator
Intervention Type
Device
Intervention Name(s)
Eurosets REMOWELL 2 oxygenator
Intervention Description
The main characteristic of REMOWELL 2 oxygenator is the presence of a filtration system for extracavitary inlet. Multilayer cascade filtration and supernatant separator leads to lipid-leukocytes depletion
Intervention Type
Device
Intervention Name(s)
LivaNova INSPIRE oxygenator
Intervention Description
INSPIRE oxygenator has no filtration system for extracavitary inlet
Primary Outcome Measure Information:
Title
post-operative delirium
Description
In-hospital incidence of post-operative delirium assessed by Confusion Assessment Method (CAM) diagnostic algorithm
Time Frame
6 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Signature of informed consent for participation in the study Age ≥65 years Patients undergoing cardiac surgery of: coronary artery bypass graft and concomitant valve replacement/repair OR double valve replacement/repair Exclusion Criteria: Any documented history of cognitive impairment estimated as a mini mental state examination < 24 points Patients who need blood prime in the cardiopulmonary bypass circuit Chronic coagulopathies ( international normalized ratio > 2 in patients without anticoagulant treatment) End stage renal disease on dialysis treatment Previous cerebrovascular accident Active cancer or immunological diseases Liver cirrhosis (platelets <100.000/uL) Decompensated diabetes Severe preoperative anemia (hemoglobin <8 g/dl).
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Lorenzo Mantovani, MD
Organizational Affiliation
Maria Cecilia Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Maria Cecilia Hospital
City
Cotignola
State/Province
Ravenna
ZIP/Postal Code
48010
Country
Italy

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Comparison of Remowell 2 and Inspire on Delirium and Cognitive Dysfunction

We'll reach out to this number within 24 hrs